Open Your FREE Demat Account Now!

N/A
indicator

Nifty Pharma

1D
1M
3M
6M
1Y
5Y
empty graph

Nifty Pharma Performance

Low

₹28,452.40

High

₹28,902.45

52 Week Range

Low

₹21,149.90

High

₹29,224.85

Previous Close ₹28,675.75
Day's Range ₹28,452.40 - ₹28,902.45
Open ₹28,598.60
52 Week Range ₹21,149.90 - ₹29,224.85
Volume 2,90,17,293

Nifty Pharma Companies

Company Name LTP (₹) Change (₹) Sector
Cipla Ltd. 1391.80 Arrow -16.50 (-1.17%) Healthcare
Dr. Reddy's Laboratories Ltd. 1380.00 Arrow -6.60 (-0.48%) Healthcare
Lupin Ltd. 1980.30 Arrow -34.70 (-1.72%) Healthcare
Torrent Pharmaceuticals Ltd. 4670.00 Arrow -57.20 (-1.21%) Healthcare
Abbott India Ltd. 26440.00 Arrow -160.00 (-0.60%) Healthcare
Ipca Laboratories Ltd. 1884.00 Arrow -15.70 (-0.83%) Healthcare
Sun Pharmaceutical Industries Ltd. 1880.00 Arrow -5.00 (-0.27%) Healthcare
Aurobindo Pharma Ltd. 1823.20 Arrow 16.00 (0.89%) Healthcare
Glenmark Pharmaceuticals Ltd. 2640.00 Arrow -19.80 (-0.74%) Healthcare
Wockhardt Ltd. 2027.20 Arrow -26.80 (-1.30%) Healthcare

All Indices

Index Name Market Value 52W High 52W Low
Nifty 50 25144.3 26373.20 22179.90
Nifty IT 31931.15 40301.40 25699.10
Nifty Next 50 72874.7 75000.40 59896.10
NIFTY50 USD Index 9244.05 10443.40 7839.85
Nifty Bank 61034.1 61764.85 49954.85
NIFTY Midcap 100 61889.5 64450.90 52032.85
Nifty 500 23734.2 24144.20 20385.65
Nifty Midcap 50 17877.45 18500.95 14804.55
Nifty 100 26083.2 26975.15 22720.45
Nifty FMCG 46833.55 55897.55 42006.00

Latest News

Nov
12
2026
EQUITY Posted on Nov 12th 2026

Alkem Laboratories informs about change in management

Alkem Laboratories has informed that, based on the recommendation of the Nomination and Remuneration Committee and approval of the Audit Committee, the Board of Directors of the Company at its meeting held today i.e. 12th November, 2026 has appointed Gopal Kothari as the Chief Financial Officer (CFO) and Key Managerial Personnel of the Company with effect from 02nd December, 2026. The meeting of the Board of Directors of the Company commenced at 11.30 am and concluded at 01.40 pm. Further, the details as required in terms of Regulation 30 read with Schedule III, Part A of the SEBI LODR Regulations and SEBI Master Circular bearing HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026 are provided in Annexure I to this letter. The above information is also available on the website of the Company www.alkemlabs.com.
The above information is a part of company’s filings submitted to BSE.
Read More
Nov
12
2026
EQUITY Posted on Nov 12th 2026

Alkem Laboratories informs about investor presentation

With reference to relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Alkem Laboratories has enclosed the press release and analyst presentation on Q2 & H1FY27 earnings and business updates and the same will be uploaded on the website of the Company.
The above information is a part of company’s filings submitted to BSE.
Read More
Nov
12
2026
EQUITY Posted on Nov 12th 2026

Lupin informs about press release

Lupin has informed that it enclosed a Press Release titled ‘Lupin Announces European Launch of Biosimilar Ranibizumab‘.
The above information is a part of company’s filings submitted to BSE.
Read More
Nov
12
2026
EQUITY Posted on Nov 12th 2026

Alkem Laboratories informs about unaudited financial results

Alkem Laboratories has informed that this is in reference to earlier intimation dated 4th November, 2026, pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations) regarding holding of Board Meeting on 12th November, 2026 to approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026. The Board of Directors at its meeting held today, i.e. 12th November, 2026 has approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026. A copy of the said Financial Results and Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the SEBI LODR Regulations is enclosed. The meeting of the Board of Directors of the Company commenced at 11.30 am and concluded at 01.40 pm. The above information is also available on the website of the Company at www.alkemlabs.com
The above information is a part of company’s filings submitted to BSE.
Read More
Nov
12
2026
EQUITY Posted on Nov 12th 2026

Alkem Laboratories informs about outcome of board meeting

Alkem Laboratories has informed that this is in reference to earlier intimation dated 04th November, 2026, pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations) regarding holding of Board Meeting on 12th November, 2026 to approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026. The Board of Directors at its meeting held today, i.e. 12th November, 2026 has approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026. A copy of the said Financial Results and Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the SEBI LODR Regulations, is enclosed. The meeting of the Board of Directors of the Company commenced at 11.30 am and concluded at 01.40 pm. The above information is also available on the website of the Company at www.alkemlabs.com
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Frequently Asked Questions

What is the Previous Close of NIFTYPHARMA index?

The previous close of NIFTYPHARMA index is ₹28535.75 as of 2026-11-13.

The total volume of NIFTYPHARMA index is 29015966.00 as of 2026-11-13.

The percentage change in value of NIFTYPHARMA index is -0.49% as of 2026-11-13.

The absolute increase in NIFTYPHARMA index value since the previous trading day is ₹-140.0 as of 2026-11-13.

A stock reaching its 52-week high indicates it has attained its highest price point in the past year. This milestone may signal strong performance and positive investor sentiment. Please note that investments are subject to market risks.

View More

People Also Ask

What is the Nifty Pharma Index?

The Nifty Pharma Index is a sectoral stock market index that represents the performance of leading pharmaceutical companies listed on the National Stock Exchange (NSE). It serves as a benchmark for tracking the Indian pharmaceutical sector.

The Nifty Pharma Index tracks the price performance of companies operating in the pharmaceutical industry. It helps market participants understand overall trends in the pharmaceutical sector and the movement of the index.

The index symbol commonly used for the Nifty Pharma Index is NIFTY PHARMA.

The Nifty Pharma Index is calculated using the free-float market capitalisation method. This method considers only the shares that are readily available for trading in the market, helping reflect the investable value of the constituent companies.

The Nifty Pharma Index focuses only on pharmaceutical sector companies, while the Nifty 500 covers companies from multiple sectors across the Indian economy. As a result, the Nifty Pharma Index provides sector-specific exposure, whereas the Nifty 500 offers broader market representation.

The Nifty Pharma Index is reviewed semi-annually in accordance with the NSE Indices methodology. During each review, constituent stocks are evaluated, and changes may be made to ensure the index continues to represent the pharmaceutical sector.

You can check the latest Nifty Pharma Index value and related market updates on stock exchange websites, financial news platforms, brokerage portals, and market-tracking applications.

To be eligible for inclusion, companies typically need to be part of the Nifty 500 universe, belong to the pharmaceutical sector, meet liquidity requirements, and satisfy other index methodology criteria specified by NSE Indices.

The base date of the Nifty Pharma Index is 1 January 2001, with a base value of 1,000.

View More
Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore